Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 60 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
Vaccinium Corymbosum from Nijlen, company number BE0698745735, closed financial year 2025 with a result of € 63,774 after tax. For that financial year Vaccinium Corymbosum recorded a gross margin of € 184,843 and equity of € 132,146. Compared with financial year 2024, the result moved from € 60,744 to € 63,774. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on June 3, 2026.
€ 132,146
▲ 91% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 63,774
▲ 5% vs 2024
Profit after tax over the fiscal year.
€ 5,259
▲ 76% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 833 paid out
1 % of the profit went to the shareholders, the rest stayed in the company.
People and assets in 2025
€ 64,477
▲ 52% vs 2024
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 9,288
▼ 13% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 241,052
▲ 3% vs 2024
€ 17,456 is repaid this year. At this pace the long-term loan is gone in ≈ 12 years.
€ 5,325
▼ 16% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 20,210
▼ 38% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|
| Gross margin | € 163,546 | € 159,827 | € 184,843 | ▲ 16% |
| Profit after taxes | € 69,536 | € 60,744 | € 63,774 | ▲ 5% |
| Equity | € 9,294 | € 69,206 | € 132,146 | ▲ 91% |
| Total debts | € 375,286 | € 321,871 | € 268,790 | ▼ 16% |
| Cash | € 5,470 | € 2,981 | € 5,259 | ▲ 76% |
| Land & buildings | € 346,923 | € 334,339 | € 314,388 | ▼ 6% |
| Retained profit | € 7,294 | € 67,206 | € 130,146 | ▲ 94% |
| Dividend | € 800 | € 833 | € 833 | |
| Bank debt | € 250,964 | € 233,508 | € 241,052 | ▲ 3% |
| Balance sheet total | € 384,581 | € 391,076 | € 400,936 | ▲ 3% |
Key figures of Vaccinium Corymbosum, fiscal years 2023 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Vaccinium Corymbosum?
What happened at Vaccinium Corymbosum in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 63,774 (▲ 5% vs 2024). Source: NBB ↗
- Wim VAN DEN EYNDE became a director. NBB
- New establishment in Nijlen. KBO
- Start of the company according to the CBE. KBO
In short
From € 69,536 profit in 2023 to € 63,774 profit in 2025.
Paid € 43,384 in corporate taxes since 2023.
Best year ever: 2023, with € 69,536 profit.
Paid out € 2,466 in dividends to the owners in total.
A new publication or filing at Vaccinium Corymbosum? We notify you, reason included.
Follow Vaccinium CorymbosumDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind Vaccinium Corymbosum is Wim VAN DEN EYNDE.
Directors
According to the 2025 annual accounts
Wim VAN DEN EYNDE
Associate
since 2019
Establishments
Establishment units
Physical locations of this company
Bogaertsheide(Kessel) 11
2560 Nijlen
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0698.745.735
- VAT number
- BE 0698.745.735
- Registered office
- Bogaertsheide(Kessel) 11, 2560 Nijlen
- Names & denominations
- Vaccinium Corymbosum
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 22 June 2018
- Peppol
- Active · Active since 11 Nov 2025
- Activities · NACE
Teelt van andere boomvruchten, kleinfruit en noten
Groothandel in groenten en fruit, muv consumptieaardappelen
Vervaardiging van andere voedingsmiddelen, neg
Verhuur en exploitatie van eigen of geleased niet-residentieel onroerend goed, exclusief terreinen
Verhuur en exploitatie van eigen of geleased residentieel onroerend goed, exclusief sociale woningen
Overige detailhandel in voedingsmiddelen, neg
Handelsbemiddeling in de groothandel in voedings- en genotmiddelen
Vervaardiging van frisdranken en water in flessen
+4